Cryptococcus species causes close to a quater of a million cases of severe disease and > 180 000 deaths...universally fatal if untreated. In this episode of MM, host Dr Vindana Chibabhai, chats to Prof Nelesh Govender about recent changes and expected changes in the diagnosis and management of Cryptococcal disease.

2022 WHO Cryptococcal Disease Management Guidelines here

ACTA Trial

Ambition Trial

About Prof Nelesh Govender:

I run a research group in medical mycology in South Africa, among a select few worldwide working in public health mycology. A major theme of my research is HIV-associated fungal diseases, many of which are life-threatening. My research activities span: 1) laboratory science (including characterisation of established/emerging fungal pathogens and diagnostic test development/evaluation), 2) population-based observational epidemiological studies, 3) cost-effectiveness modelling of public health interventions and treatments and 4) clinical trials. This research is aligned to my work as a centre head at the National Institute for Communicable Diseases (www.nicd.ac.za) where I run South Africa’s national mycology reference laboratory. Our group serves as a World Health Organization Collaborating Centre for antimicrobial resistance. Our public health research is primarily funded through NICD but also partly through grants from the US National Institutes of Health, US Centers for Disease Control and Prevention (CDC), CDC Foundation, Bill and Melinda Gates Foundation, UK Medical Research Council, UK National Institute for Health Research and NHLS Research Trust.

Twitter @neleshg

Visit the Microbe Mail website to sign up for updates

E-mail: [email protected]

Instagram: Microbe_Mail 

Twitter: @microbemail

Facebook: Microbe Mail

Pinterest: @mailmicrobe